Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577–80.
Article
CAS
PubMed
Google Scholar
Rubin BP, Blanke Cd Fau - Demetri GD, Demetri Gd Fau - Dematteo RP, Dematteo Rp Fau - Fletcher CDM, Fletcher Cd Fau - Goldblum JR, Goldblum Jr Fau - Lasota J, Lasota J Fau - Lazar A, Lazar A Fau - Maki RG, Maki Rg Fau - Miettinen M, Miettinen M Fau - Noffsinger A et al: Protocol for the examination of specimens from patients with gastrointestinal stromal tumor. (1543–2165 (Electronic)).
Fletcher CDM, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O’Leary TJ, Remotti H, Rubin BP, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33(5):459–65.
Article
PubMed
Google Scholar
Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70–83.
Article
PubMed
Google Scholar
Patel N, Benipal B: Incidence of gastrointestinal stromal tumors in the United States from 2001–2015: a United States cancer statistics analysis of 50 states. (2168–8184 (Print)).
Howlader N NA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds): SEER Cancer Statistics Review, 1975–2018. In. Edited by National Cancer Institute. Bethesda M; 2021.
Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen C-J, Joseph N, Singer S, Griffith DJ, Haley A, Town A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708–10.
Article
CAS
PubMed
Google Scholar
Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020;111(2):312–22.
Article
CAS
PubMed
Google Scholar
Cannarile MA, Weisser M, Jacob W, Jegg A-M, Ries CH, Rüttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. 2017;5(1):53.
Article
PubMed
PubMed Central
Google Scholar
Pauls K, Merkelbach-Bruse S, Thal D, Büttner R, Wardelmann E. PDGFRα- and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features. Histopathology. 2005;46(2):166–75.
Article
CAS
PubMed
Google Scholar
Szucs Z, Thway K, Fisher C, Bulusu R, Constantinidou A, Benson C. Graaf WTvd, Jones RL: Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol. 2017;13(1):93–107.
Article
CAS
PubMed
Google Scholar
Hemming ML, Heinrich MC, Bauer S, George S. Translational insights into gastrointestinal stromal tumor and current clinical advances. Ann Oncol. 2018;29(10):2037–45.
Article
CAS
PubMed
Google Scholar
Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PWT, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol. 2014;32(15):1563–70.
Article
CAS
PubMed
PubMed Central
Google Scholar
Joensuu H, Wardelmann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Cameron S, Hohenberger P, et al. Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: an exploratory analysis of a randomized clinical trial. JAMA Oncol. 2017;3(5):602–9.
Article
PubMed
PubMed Central
Google Scholar
Joensuu H, Rutkowski P, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Braconi C, Bordoni A, Magnusson MK, et al. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. J Clin Oncol. 2015;33(6):634–42.
Article
CAS
PubMed
Google Scholar
Abrams T, Connor A, Fanton C, Cohen SB, Huber T, Miller K, Hong EE, Niu X, Kline J, Ison-Dugenny M, et al. Preclinical antitumor activity of a novel anti–c-KIT antibody–drug conjugate against mutant and wild-type c-KIT–positive solid tumors. Clin Cancer Res. 2018;24(17):4297–308.
Article
CAS
PubMed
Google Scholar
Kim J-O, Kim K-H, Baek EJ, Park B, So MK, Ko BJ, Ko H-J, Park SG. A novel anti-c-Kit antibody–drug conjugate to treat wild-type and activating-mutant c-Kit-positive tumors. Mol Oncol. 2022;16(6):1290–308.
Article
PubMed
CAS
Google Scholar
Lopus M, Oroudjev E, Wilson L, Wilhelm S, Widdison W, Chari R, Jordan MA. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther. 2010;9(10):2689–99.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cassady JM, Chan KK, Floss HG, Leistner E: Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull (Tokyo). 2004;52(1):1–26.
Joubert N, Beck A, Dumontet C, Denevault-Sabourin C. Antibody–drug conjugates: the last decade. Pharmaceuticals. 2020;13(9):245.
Article
CAS
PubMed Central
Google Scholar
Lambert JM, Chari RVJ. Ado-trastuzumab Emtansine (T-DM1): an antibody–drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem. 2014;57(16):6949–64.
Article
CAS
PubMed
Google Scholar
Zhang D, Guo Y, Zhao Y, Yu L, Chang Z, Pei H, Huang J, Chen C, Xue H, Xu X, et al. Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression. Microb Cell Fact. 2021;20(1):67.
Article
CAS
PubMed
PubMed Central
Google Scholar
Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(11):1870–7.
Article
CAS
PubMed
Google Scholar
Jiang X, Gurel O, Mendiaz EA, Stearns GW, Clogston CL, Lu HS, Osslund TD, Syed RS, Langley KE, Hendrickson WA. Structure of the active core of human stem cell factor and analysis of binding to its receptor kit. EMBO J. 2000;19(13):3192–203.
Article
CAS
PubMed
PubMed Central
Google Scholar
Haglund K, Dikic I. The role of ubiquitylation in receptor endocytosis and endosomal sorting. J Cell Sci. 2012;125(2):265–75.
Article
CAS
PubMed
Google Scholar
Blay J-Y, Kang Y-K, Nishida T, von Mehren M. Gastrointestinal stromal tumours. Nat Rev Dis Primers. 2021;7(1):22.
Article
PubMed
Google Scholar
Tilayov T, Hingaly T, Greenshpan Y, Cohen S, Akabayov B, Gazit R, Papo N. Engineering stem cell factor ligands with different c-Kit agonistic potencies. Molecules. 2020;25(20):4850.
Article
CAS
PubMed Central
Google Scholar
Dahlen DD, Lin NL, Liu Y-C, Broudy VC. Soluble c-kit receptor blocks stem cell factor bioactivity in vitro. Leuk Res. 2001;25(5):413–21.
Article
CAS
PubMed
Google Scholar
Choudhary S, Pardo A, Rosinke R, Batra JK, Barth S, Verma RS. Targeting c-kit receptor in neuroblastomas and colorectal cancers using stem cell factor (SCF)-based recombinant bacterial toxins. Appl Microbiol Biotechnol. 2016;100(1):263–77.
Article
CAS
PubMed
Google Scholar
Studier FW. Protein production by auto-induction in high-density shaking cultures. Protein Expr Purif. 2005;41(1):207–34.
Article
CAS
PubMed
Google Scholar
Guzmán-Verduzco L-M, Kupersztoch YM. Export and processing analysis of a fusion between the extracellular heat-stable enterotoxin and the periplasmic B subunit of the heat-labile enterotoxin in Escherichia coli. Mol Microbiol. 1990;4(2):253–64.
Article
PubMed
CAS
Google Scholar
Henze J, Mühlenberg T, Simon S, Grabellus F, Rubin B, Taeger G, Schuler M, Treckmann J, Debiec-Rychter M, Taguchi T, et al. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. PLoS ONE. 2012;7(5):e37776–e37776.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chen Y, Guo Y, Zhao W, Tina Ho WT, Fu X, Zhao ZJ. Identification of an orally available compound with potent and broad FLT3 inhibition activity. Oncogene. 2016;35(23):2971–8.
Article
CAS
PubMed
Google Scholar
Balachandran VP, DeMatteo RP. Gastrointestinal stromal tumors: who should get imatinib and for how long? Adv Surg. 2014;48(1):165–83.
Article
PubMed
PubMed Central
Google Scholar
Napolitano A, Vincenzi B. Secondary KIT mutations: the GIST of drug resistance and sensitivity. Br J Cancer. 2019;120(6):577–8.
Article
PubMed
PubMed Central
Google Scholar
Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11(11):4182–90.
Article
CAS
PubMed
Google Scholar
Oliver TG, Meylan E, Chang GP, Xue W, Burke JR, Humpton TJ, Hubbard D, Bhutkar A, Jacks T. Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. Mol Cell. 2011;43(1):57–71.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pochampally R, Fodera B, Chen L, Shao W, Levine EA, Chen J. A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells. Oncogene. 1998;17(20):2629–36.
Article
CAS
PubMed
Google Scholar
Widdison W, Wilhelm S, Veale K, Costoplus J, Jones G, Audette C, Leece B, Bartle L, Kovtun Y, Chari R: Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies. Mol Pharm. 2015;12(6):1762–73.
Riss T, Moravec R, Niles A, Benink H. Cell viability assays. Assay Guid Man. 2013.
Google Scholar
Houen G. Therapeutic antibodiestherapeutic antibodies: an overview. In: Houen G, editor. Therapeutic Antibodies: Methods and Protocols. edn. New York, NY: Springer US; 2022. p. 1–25.
Chapter
Google Scholar
Zhao Y, Zhang D, Guo Y, Lu B, Zhao Z, Xu X, Chen Y. Tyrosine kinase ROR1 as a target for anti-cancer therapies. Front Oncol. 2021;11:680834.
Article
PubMed
PubMed Central
Google Scholar
Doody JF, Wang Y, Patel SN, Joynes C, Lee SP, Gerlak J, Rolser RL, Li Y, Steiner P, Bassi R, et al. Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non–small cell lung cancers. Mol Cancer Ther. 2007;6(10):2642–51.
Article
CAS
PubMed
Google Scholar
Li Y, Li H, Wang M-N, Lu D, Bassi R, Wu Y, Zhang H, Balderes P, Ludwig DL, Pytowski B, et al. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. Blood. 2004;104(4):1137–44.
Article
CAS
PubMed
Google Scholar
Sanford D, Blum WG, Ravandi F, Klisovic RB, Borthakur G, Walker AR, Garcia-Manero G, Marcucci G, Wierda WG, Whitman SP, et al. Efficacy and safety of an anti-FLT3 antibody (LY3012218) in patients with relapsed acute myeloid leukemia. J Clin Oncol. 2015;33(15_suppl):7059–7059.
Article
Google Scholar
Shih LB, Lu H, Xuan H, Goldenberg DM. Internalization and intracellular processing of an anti B-cell lymphoma monoclonal antibody, ll2. Int J Cancer. 1994;56(4):538–45.
Article
CAS
PubMed
Google Scholar
Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HTC, Beers SA, French RR, Cox KL, Davies AJ, et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood. 2011;118(9):2530–40.
Article
PubMed
Google Scholar
Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, Engelberts PJ, Parren PWHI, van de Winkel JGJ, Taylor RP. Loss of CD20 and bound CD20 antibody from opsonized B Cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J Immunol. 2011;187(6):3438–47.
Article
CAS
PubMed
Google Scholar
Chang RB, Beatty GL. The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance. J Leukoc Biol. 2020;108(1):363–76.
Article
CAS
PubMed
Google Scholar
Lebegge E, Arnouk SM, Bardet PMR, Kiss M, Raes G, Van Ginderachter JA. Innate immune defense mechanisms by myeloid cells that hamper cancer immunotherapy. Front Immunol. 2020;11:1395–1395.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yoon H, Tang C-M, Banerjee S, Delgado AL, Yebra M, Davis J, Sicklick JK. TGF-β1-mediated transition of resident fibroblasts to cancer-associated fibroblasts promotes cancer metastasis in gastrointestinal stromal tumor. Oncogenesis. 2021;10(2):13–13.
Article
CAS
PubMed
PubMed Central
Google Scholar
Czajkowsky DM, Hu J, Shao Z, Pleass RJ. Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med. 2012;4(10):1015–28.
Article
CAS
PubMed
PubMed Central
Google Scholar
Erben U, Thiel E, Notter M. Differential effects of a stem cell factor-immunoglobulin fusion protein on malignant and normal hematopoietic cells. Can Res. 1999;59(12):2924–30.
CAS
Google Scholar